Drugs / ATG-031
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT06028373 Comparator | Dec 2023 → Apr 2026 | B-cell non-Hodgkin lymphoma, cancer | Antengene Biologics Limited | Terminated | No outcome recorded Stop: Business |
Press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-12-11 | Antengene Corporation | Antengene Announces the Study of Anti-CD24 Monoclonal Antibody ATG-031 Dosed Its First Patient in the United States antengene.com ↗ |
| 2023-09-21 | Antengene Corporation | Antengene Announces Phase I Study of Anti-CD24 Monoclonal Antibody ATG-031 antengene.com ↗ |
| 2023-05-18 | Antengene Corporation | Antengene Announces Clearance of U.S. IND for the Phase I Trial of First-in-Class Anti-CD24 Monoclonal Antibody ATG-031 antengene.com ↗ |
| 2022-11-21 | Antengene Corporation | Oral Presentation on Antengene's Anti-CD24 Monoclonal Antibody ATG-031 Selected for SITC's Top 100 Abstracts antengene.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ATG-031 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06028373 ↗ |
| Route | Intravenous | “ATG-031 will be infused Q3W on Day 1 of each cycle” NCT06028373 ↗ |